Soft Tissue Sarcoma (STS)
Conditions
Keywords
Soft Tissue Sarcoma, Pazopanib, F18-FDG PET/CT
Brief summary
Soft Tissue Sarcoma (STS) is a rare tumor but can grow in different areas, for example, in 60% in limbs and about 20 % in retroperitoneum; and frequently is inoperable. Despite novel therapy in advanced cases survival is still short, approximately 12 month. Pazopanib oral angiogenesis inhibitor was recently shown as promising drug for advanced pretreated STS. Functional imaging especially F18-FDG PET/CT is a good modality for FDG avid tumor either for pre- / post- treatment evaluation or follow up. Early detection of treatment response to therapy by whole body FDG PET/CT allows for change of treatment as early as possible,when the tumor is non-responsive before serious side effects appear or before depletion of body resources. The aim of the study is to investigate the contribution of FDG PET/CT to assessment of treatment response.
Interventions
OTHERF18-FGD PET/CT
Sponsors
Hadassah Medical Organization
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with advanced Soft Tissue Sarcoma prior to pazopanib treatment
Exclusion criteria
* Other treatment * FDG negative tumor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Measure of extent and intensity (standardized uptake value - SUV) of disease demonstrated on PET/CT images before and after treatment. | 1 week |
| determination of treatment efficiency by comparison of PET data (SUV) with CT changes (cm)in 3 studies and clinical information. | 4 week |
Secondary
| Measure | Time frame |
|---|---|
| prediction of treatment efficiency | 6 weeks |
Countries
Israel
Contacts
Primary ContactMarina Orevi, MD
Backup ContactDaniela Katz, MD
Outcome results
None listed